The UK and US have reached a significant trade agreement that will guarantee no levies on UK pharmaceutical products going into the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these key exports will stay at nothing for a timeframe of 36 months.
This deal follows earlier statements to dramatically increase tariffs on branded drug imports, with figures floated up to double the cost.
"This arrangement between the UK bolsters the global environment for new treatments and introduces much-needed equity to transatlantic medicine commerce," an announcement said.
Economic Impact
Medicines are one of the the United Kingdom's biggest export categories to the US, which is clearly the primary destination for major UK drugmakers.
Export figures reveal that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products totaling billions to the US. This value represented a significant portion of total UK exports in that period.
"This deal protects employment, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The pact involves several specific pledges from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to increase overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, repayments exceeded 20%.
Recent Tensions
The deal comes amid a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by arguments that US customers were paying several times more for the same drugs than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been paused or scrapped, while substantial funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
